Published in Gene Therapy Weekly, November 13th, 1995
The patent, No. 5,460,959 was filed by the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (MIT), and was exclusively licensed to Somatix in 1988. A European patent was granted on the corresponding European application in January 1995.
The patent's claims are broad, covering the use of retrovirally transduced human fibroblasts bound to a support matrix.
Fibroblasts have been identified over the course of Somatix's preclinical work as having...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.